Eugenio Piro

561 total citations
15 papers, 115 citations indexed

About

Eugenio Piro is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Eugenio Piro has authored 15 papers receiving a total of 115 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 6 papers in Genetics and 5 papers in Molecular Biology. Recurrent topics in Eugenio Piro's work include Multiple Myeloma Research and Treatments (9 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Hematopoietic Stem Cell Transplantation (3 papers). Eugenio Piro is often cited by papers focused on Multiple Myeloma Research and Treatments (9 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Hematopoietic Stem Cell Transplantation (3 papers). Eugenio Piro collaborates with scholars based in Italy, Canada and United States. Eugenio Piro's co-authors include Stefano Molica, S. Molica, Luciano Levato, Guido Carillio, Fortunato Morabito, Francesca Ronco, Giuseppa Penna, Caterina Alati, Iolanda Donatella Vincelli and Domenico Levato and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Journal of Cancer.

In The Last Decade

Eugenio Piro

14 papers receiving 112 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eugenio Piro Italy 7 76 51 49 19 13 15 115
Rupali Bhave United States 6 86 1.1× 46 0.9× 67 1.4× 18 0.9× 8 0.6× 18 168
Valentín Cabañas Spain 6 66 0.9× 41 0.8× 51 1.0× 20 1.1× 8 0.6× 11 106
Merih Kızıl Çakar Türkiye 7 67 0.9× 33 0.6× 15 0.3× 32 1.7× 10 0.8× 40 125
Grzegorz Charliński Poland 8 70 0.9× 62 1.2× 56 1.1× 21 1.1× 6 0.5× 23 132
Othman Salim Akhtar United States 6 39 0.5× 44 0.9× 20 0.4× 41 2.2× 10 0.8× 25 114
Kristiina Kananen Finland 6 55 0.7× 97 1.9× 55 1.1× 11 0.6× 11 0.8× 7 179
Nina Shah United States 4 97 1.3× 65 1.3× 66 1.3× 10 0.5× 8 0.6× 5 124
Habib El‐Khoury United States 6 60 0.8× 28 0.5× 32 0.7× 21 1.1× 6 0.5× 17 102
Laure Morisset France 4 70 0.9× 34 0.7× 42 0.9× 39 2.1× 6 0.5× 5 119
Elena Guggiari Italy 5 117 1.5× 25 0.5× 15 0.3× 13 0.7× 10 0.8× 9 134

Countries citing papers authored by Eugenio Piro

Since Specialization
Citations

This map shows the geographic impact of Eugenio Piro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eugenio Piro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eugenio Piro more than expected).

Fields of papers citing papers by Eugenio Piro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eugenio Piro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eugenio Piro. The network helps show where Eugenio Piro may publish in the future.

Co-authorship network of co-authors of Eugenio Piro

This figure shows the co-authorship network connecting the top 25 collaborators of Eugenio Piro. A scholar is included among the top collaborators of Eugenio Piro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eugenio Piro. Eugenio Piro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Alati, Caterina, Gaetana Porto, Mark Greve, et al.. (2025). SLAMF7: A Potential Target for CAR T-Cell Therapy in Multiple Myeloma. Cancers. 17(21). 3471–3471.
2.
Molica, Stefano, et al.. (2018). A simple score based on geriatric assessment predicts survival in elderly newly diagnosed chronic lymphocytic leukemia patients. Leukemia & lymphoma. 60(3). 845–847. 12 indexed citations
3.
Piro, Eugenio, Maria Lentini, Luciano Levato, Antonio Russo, & S. Molica. (2018). Sustained Erythroid Response in a Patient with Myelofibrosis Receiving Concomitant Treatment with Ruxolitinib and Deferasirox. Chemotherapy. 63(2). 107–110. 3 indexed citations
4.
5.
6.
Martino, Massimo, Maurizio Postorino, Giuseppe Messina, et al.. (2013). Long-Term Results in Multiple Myeloma After High-Dose Melphalan and Autologous Transplantation According to Response Categories in the Era of Old Drugs. Clinical Lymphoma Myeloma & Leukemia. 14(2). 148–154. 12 indexed citations
7.
8.
Petruzziello, Fara, Pio Zeppa, Giuseppe Ciancia, et al.. (2011). Cytological and histological detection of amyloid deposits in bone marrow of patients affected by multiple myeloma. Leukemia & lymphoma. 52(12). 2304–2307. 17 indexed citations
9.
Guglielmelli, Tommasina, Sara Bringhen, Francesca Gay, et al.. (2011). Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. European Journal of Cancer. 47(6). 814–818. 12 indexed citations
10.
Piro, Eugenio & S. Molica. (2011). A Systematic Review on the Use of Bortezomib in Multiple Myeloma Patients with Renal Impairment: What Is the Published Evidence?. Acta Haematologica. 126(3). 163–168. 12 indexed citations
11.
Piro, Eugenio, et al.. (2011). Reversal of Leukostasis-Related Pulmonary Distress Syndrome After Leukapheresis and Low-Dose Chemotherapy in Acute Myeloid Leukemia. Journal of Clinical Oncology. 29(26). e725–e726. 14 indexed citations
12.
13.
Calimeri, Teresa, Edmondo Battista, Francesco Conforti, et al.. (2010). SCID-Synth-Hu: a Novel Multiple Myeloma Model for In Vivo Expansion of Primary Cells. Blood. 116(21). 452–452. 1 indexed citations
14.
Guglielmelli, Tommasina, Sara Galimberti, Alfredo Berruti, et al.. (2009). Sequential Therapy with IMID's in Relapsed-Refractory Multiple Myeloma Patients.. Blood. 114(22). 2888–2888. 2 indexed citations
15.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rupali Bhave Breakdown of academic impact, for papers by Valentín Cabañas Breakdown of academic impact, for papers by Merih Kızıl Çakar Breakdown of academic impact, for papers by Grzegorz Charliński Breakdown of academic impact, for papers by Othman Salim Akhtar Breakdown of academic impact, for papers by Kristiina Kananen Breakdown of academic impact, for papers by Nina Shah Breakdown of academic impact, for papers by Habib El‐Khoury Breakdown of academic impact, for papers by Laure Morisset Breakdown of academic impact, for papers by Elena Guggiari
Rankless by CCL
2026